Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) was the recipient of a large decline in short interest in October. As of October 15th, there was short interest totaling 96 shares, a decline of 73.7% from the September 30th total of 365 shares. Based on an average daily volume of 2 shares, the days-to-cover ratio is currently 48.0 days. Currently, 0.0% of the company’s stock are sold short.
Basilea Pharmaceutica Stock Performance
Shares of OTCMKTS BPMUF remained flat at $76.25 during trading hours on Friday. The business has a 50 day simple moving average of $76.94 and a 200-day simple moving average of $69.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 6.60 and a quick ratio of 5.97. Basilea Pharmaceutica has a 52-week low of $59.29 and a 52-week high of $77.40.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG is a Switzerland-based biopharmaceutical company focused on discovering, developing and commercializing medicines for serious bacterial and fungal infections, as well as selected oncology indications. The company is headquartered in Basel and was established in 2000 as a spin-off from Roche.
Basilea’s principal products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive fungal infections, and Zevtera (ceftobiprole), a cephalosporin antibiotic developed for several serious bacterial infections.
Further Reading
- Five stocks we like better than Basilea Pharmaceutica
- Microsoft Earnings Expose a Growing Divide in the Magnificent 7 AI Trade
- Silicon Shock: Intel’s 25% Valuation Reset
- Advanced Micro Devices’ Meta Platforms Partnership Goes Beyond a $1 Billion Investment
- Chipotle’s $32 Floor: Is a Major Stock Rebound Coming?
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
